| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.04 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.04 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.05 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.074 | 0.05 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.082 | 0.05 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.05 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.074 | 0.05 |